Understand the source comparison
Do Peptides Help with Fat Loss: [Compound Class] Comparison
The table below compares major peptide classes used in fat loss research protocols, organized by primary mechanism, typical dosing regimens, and documented efficacy. This comparison assumes proper reconstitution, sterile handling, and institutional oversight.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares major peptide classes used in fat loss research protocols, organized by primary mechanism, typical dosing regimens, and documented efficacy. This comparison assumes proper reconstitution, sterile handling, and institutional oversight. Recreational use introduces variables beyond the scope of controlled research.
- GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)
- Delays gastric emptying, extends satiety hormone elevation, reduces caloric intake by 25–35%
- 2.5–15mg weekly (titrated over 16–20 weeks)
- 12–21% total body weight, 90–95% from fat mass
- Preserved (minimal loss)
- Strongest clinical evidence for fat-specific weight reduction; approved by FDA for obesity treatment; requires gradual titration
- Dual GIP/GLP-1 Agonists (Mazdutide, Survodutide)
- Combines incretin signaling with glucagon receptor activation for enhanced thermogenesis
- 3–12mg weekly (research stage)
- 15–18% total body weight in Phase 2 trials
- Preserved or slight gain
- Emerging class with potentially superior efficacy to single-agonist GLP-1 compounds; not yet FDA-approved for clinical use
- Growth Hormone Secretagogues (CJC-1295, Ipamorelin, Hexarelin)
- Stimulates pituitary GH release, activates hormone-sensitive lipase in adipocytes
- 100–300mcg daily (evening injection)
- 2–4 kg fat mass over 12–24 weeks
- Gain of 1–2 kg lean mass
- Modest fat loss with concurrent muscle preservation; most effective when combined with resistance training
- Ghrelin Mimetics (MK-677)
- Oral ghrelin receptor agonist, increases appetite and GH secretion
- 10–25mg daily (oral)
- Variable; often neutral or slight weight gain
- Gain of 1–3 kg lean mass
- Increases hunger substantially; used primarily for muscle preservation during caloric deficit, not standalone fat loss
- Lipotropic Peptide Blends (Lipo-C)
- Methionine, inositol, choline for hepatic lipid metabolism
- 1–2mL intramuscular, 2–3× weekly
- Minimal independent effect; 0.5–1.5 kg over 12 weeks
- Neutral
- Weak evidence for standalone efficacy; occasionally used as adjunct to primary fat loss protocol